Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist - Test2 - elhamkhani - TriplyDB

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

http://www.wikidata.org/entity/Q28344003

about

Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine Crystal structure of the human receptor activity-modifying protein 1 extracellular domain Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system Neuropeptides and their receptors: innovative science providing novel therapeutic targets Adrenomedullin signaling is necessary for murine lymphatic vascular development.Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37)Migraine in the era of precision medicine Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature CGRP may play a causative role in migraine Calcitonin gene-related peptide: physiology and pathophysiology Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists Role of calcitonin receptor-like receptor in colonic motility and inflammation Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine.Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding.A reactive oxygen species-mediated component in neurogenic vasodilatation.Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review.Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ET(A)-receptor complexes TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation.Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.Possible site of action of CGRP antagonists in migraine.One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010.Diencephalic and brainstem mechanisms in migraine.Neurogenic inflammation in the context of migraine.The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system.Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells.Finding new drug targets for the treatment of migraine attacks.Therapies in development for the treatment of migraine.Effects of the CGRP receptor antagonist BIBN4096BS on capsaicin-induced carotid haemodynamic changes in anaesthetised pigs Calcitonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in migraine.The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature.Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat

P2860

Q24632671-C4F547F5-A78F-4600-8B0A-AFCA7F4298E0 Q24644526-47891702-BAD2-48AE-9256-9AFB0DFBCA7D Q24646305-C675BFD4-CE29-4DCE-A3D5-BEBD6B7A1246 Q24670220-6BE50E14-B96B-4906-B452-34F49214A517 Q24671300-330B9BBF-E525-4485-9F87-E0FBA0D30DF4 Q24671891-D804F383-3D52-4D05-B2B2-658ED723CBC0 Q24677292-516B1461-F6B1-44E4-BEFF-C893A6929907 Q26748947-12867364-19DC-4D25-9545-BFA666938CDD Q28215715-7FAA57E0-8E0D-49EB-BD39-3BFF46D8E124 Q28216666-5E231808-089A-4765-A27A-E80CED944CC0 Q28249298-BDC51FE5-2E4E-4485-93C0-58565B427187 Q28300031-F46A03A5-9B89-4216-A62E-C00D171D12C1 Q28345802-CA2FC894-BC0E-4C18-81D7-2517F29A98DD Q28354243-8EBC5CA8-19A5-4E22-9C8F-36F830A218B5 Q28577195-DF08F73F-A191-4EBB-B21B-7F05666F4CE8 Q28577506-55DF5E7E-872D-4A41-95FD-1EE6A315232C Q28582321-4CF652D0-F679-4365-B87F-56FFD8EDD976 Q28590329-FCDE0CF5-8229-45BA-8A84-616284ECC23C Q30486707-DE585111-044E-407D-8651-4F093C777568 Q30496689-F1ECB112-0D7C-412B-82FE-9C4AC87F55C8 Q33246847-D06ACD4A-C91F-477D-B071-005C71C6F2F3 Q33315296-257898D9-3C70-46D6-9197-DE534050DA37 Q33516651-5EF4D0E3-9CAF-4699-A715-A6C06DB44B3F Q33524521-1AE10C85-1714-435E-885F-55E06952E88C Q33598651-C151325C-7322-4C6B-92E6-260688D7023E Q33746184-D7C99677-E6F5-4D75-9FC8-5505090040B2 Q33859031-A6C782D2-102A-46CA-A16D-F1615E182A65 Q34094599-225DA2F4-743E-4AC8-8A11-48169E82C568 Q34169056-3D459682-D4E2-4295-9B05-68DD52798255 Q34180539-FF078EFA-7088-4C62-9ACC-D7A29BC490BA Q34217686-1C856FD1-BEF7-4CCE-AF11-5EA6195AF8B2 Q34218309-5E6C8307-8551-4D79-B305-2A7C5FE9EADC Q34228530-4761400D-499D-4400-81AB-E120F1908A8B Q34843051-EAB5F53D-3C32-49D0-9534-DB4E2AC04E66 Q34954050-A4A13B4F-6F53-45EC-BF3A-92C245358535 Q35011915-D2C640EB-9508-40EB-B27D-8A09F2F1E35E Q35045720-808B4394-2725-4FB5-A9DC-D66726714AC9 Q35047480-07FBC613-FB32-4663-AD9F-7C61C981FBC0 Q35047484-55DBB616-6C80-4E86-96F2-69D707A37754 Q35048367-C2CC079D-7433-484A-B681-D22015F30566

P2860

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

http://www.wikidata.org/entity/Q28344003

description

2000 nî lūn-bûn

@nan

2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@ast

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@en

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@nl

type

label

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@ast

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@en

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@nl

prefLabel

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@ast

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@en

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@nl

P1433

Q28344003-C742C98B-869B-4E89-A299-E7A67F61E14C

P1476

Q28344003-E663FA92-A795-4D7C-8A1E-A014E7313750

P2093

Q28344003-18A037F3-D956-4276-A47A-E6ABDAE636D3

Q28344003-21E46C16-F785-4012-B374-A0CAA0FC74EB

Q28344003-233ADD90-37B0-4C1F-9189-0E20B913C01E

Q28344003-41EE66B8-95AC-4F85-A4AE-A213FE2AD943

Q28344003-5A3CE2A2-9EF1-4CCE-A763-3BE7C9177081

Q28344003-D13725C2-F37E-4DF0-B235-1E66F8001497

Q28344003-FFAD1316-CAA4-4815-BD54-CE156DECC20E

P2860

Q28344003-08A53C98-EBD5-4E4F-9549-40008E70B0A9

Q28344003-0B1DCD3A-7A30-4608-AC4B-89B3A9A64E38

Q28344003-31B844B1-3425-40BE-B0B1-1687F02BD061

Q28344003-3F69A632-3E66-4673-B1DD-9EDB3B338176

Q28344003-8883B6C6-4801-4624-B3EB-0CDE691EFD2F

Q28344003-9390C6EF-6631-4831-822F-AB086B0C1726

Q28344003-ACC9A659-12AD-43BD-B1BE-D6CAA0C0D8C3

Q28344003-B8FF546E-1E26-4422-BA86-E81E3DEA7701

Q28344003-BAF12F51-1314-4C9D-A161-F63BD679FB53

Q28344003-C03D33B7-A35D-4E65-AEF6-2DAFAD56E552

P304

Q28344003-EB2580B2-D350-4ABD-A714-39DC4ACCF4C6

P31

Q28344003-630E8C89-B81E-4750-829E-D6E5F25553EC

P356

Q28344003-9AFDB83D-86D9-4331-B964-9CD102152FA7

P407

Q28344003-097D0BA4-2779-42CF-B517-A995412D57E5

P433

Q28344003-E300F55B-69BD-4022-A7F5-F5AE3C7FE114

P478

Q28344003-DA2AAFAE-3869-4B42-A982-48CEBA94B5C8

P577

Q28344003-92C8F6E6-AF11-4906-8892-E1CF0E693B21

P5875

Q28344003-82781786-A631-4E1A-978F-480C907E015A

P698

Q28344003-0F35D8CD-9024-43B0-BB35-E8030BA33098

P921

Q28344003-DDE5FC62-9923-4E8B-8882-A21F20D794D9

P932

Q28344003-55ED56C6-F869-4791-A31E-DEE795F92E5C

P356

P1433

British Journal of Pharmacology

P1476

Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist

@en

P2093

D Wu

http://www.w3.org/2001/XMLSchema#string

G Hallermayer

http://www.w3.org/2001/XMLSchema#string

H Doods

http://www.w3.org/2001/XMLSchema#string

K Rudolf

http://www.w3.org/2001/XMLSchema#string

M Entzeroth

http://www.w3.org/2001/XMLSchema#string

W Eberlein

http://www.w3.org/2001/XMLSchema#string

W Engel

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

A cDNA encoding the calcitonin gene-related peptide type 1 receptor

Central nervous system binding sites for calcitonin and calcitonin gene-related peptide.

Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide.

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

Neurovascular and molecular mechanisms in migraine headaches.

Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role.

pAx and competitive drug antagonism

P304

420-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0703110

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227751077

http://www.w3.org/2001/XMLSchema#string

P698

10711339

http://www.w3.org/2001/XMLSchema#string

P921

P932

1571877

http://www.w3.org/2001/XMLSchema#string